dc.contributor.author | Negi, Neema | |
dc.contributor.author | Griffin, Matthew D. | |
dc.date.accessioned | 2021-01-04T14:01:21Z | |
dc.date.available | 2021-01-04T14:01:21Z | |
dc.date.issued | 2020-01-29 | |
dc.identifier.citation | Negi, Neema, & Griffin, Matthew D. (2020). Effects of mesenchymal stromal cells on regulatory T cells: Current understanding and clinical relevance. STEM CELLS, 38(5), 596-605. doi:https://doi.org/10.1002/stem.3151 | en_IE |
dc.identifier.issn | 1066-5099 | |
dc.identifier.uri | http://hdl.handle.net/10379/16397 | |
dc.description.abstract | The immunomodulatory potential of mesenchymal stromal cells (MSCs) and regulatory T cells (T-reg) is well recognized by translational scientists in the field of regenerative medicine and cellular therapies. A wide range of preclinical studies as well as a limited number of human clinical trials of MSC therapies have not only shown promising safety and efficacy profiles but have also revealed changes in T-reg frequency and function. However, the mechanisms underlying this potentially important observation are not well understood and, consequently, the optimal strategies for harnessing MSC/T-reg cross-talk remain elusive. Cell-to-cell contact, production of soluble factors, reprogramming of antigen presenting cells to tolerogenic phenotypes, and induction of extracellular vesicles ("exosomes") have emerged as possible mechanisms by which MSCs produce an immune-modulatory milieu for T-reg expansion. Additionally, these two cell types have the potential to complement each other's immunoregulatory functions, and a combinatorial approach may exert synergistic effects for the treatment of immunological diseases. In this review, we critically assess recent translational research related to the outcomes and mechanistic basis of MSC effects on T-reg and provide a perspective on the potential for this knowledge base to be further exploited for the treatment of autoimmune disorders and transplants. | en_IE |
dc.description.sponsorship | This publication has emanated from research conducted with the financial support of Science Foundation Ireland (SFI) and is co‐funded under the European Regional Development Fund under Grant Number 13/RC/2073. It has also received funding from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska‐Curie grant agreement No 713690 (NN and MDG). MDG is additionally supported by grants from the European Commission [Horizon 2020 Collaborative Health Project NEPHSTROM (grant number 634086) and FP7 Collaborative Health Project VISICORT (grant number 602470)], from Science Foundation Ireland [REMEDI Strategic Research Cluster (grant number 09/SRC/B1794)] and the European Regional Development Fund. | en_IE |
dc.format | application/pdf | en_IE |
dc.language.iso | en | en_IE |
dc.publisher | AlphaMed Press and Wiley | en_IE |
dc.relation.ispartof | Stem Cells (Dayton, Ohio) | en |
dc.rights | Attribution-NonCommercial-NoDerivs 3.0 Ireland | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/3.0/ie/ | |
dc.subject | LEUKEMIA INHIBITORY FACTOR | en_IE |
dc.subject | VERSUS-HOST-DISEASE | en_IE |
dc.subject | STEM-CELLS | en_IE |
dc.subject | DENDRITIC CELLS | en_IE |
dc.subject | PROSTAGLANDIN E-2 | en_IE |
dc.subject | EXTRACELLULAR VESICLES | en_IE |
dc.subject | ANTIINFLAMMATORY PHENOTYPE | en_IE |
dc.subject | LIVER-TRANSPLANTATION | en_IE |
dc.subject | ACUTE REJECTION | en_IE |
dc.subject | TREG CELLS | en_IE |
dc.title | Effects of mesenchymal stromal cells on regulatory T cells: Current understanding and clinical relevance | en_IE |
dc.type | Article | en_IE |
dc.date.updated | 2020-12-19T17:25:25Z | |
dc.identifier.doi | 10.1002/stem.3151 | |
dc.local.publishedsource | https://doi.org/10.1002/stem.3151 | en_IE |
dc.description.peer-reviewed | peer-reviewed | |
dc.contributor.funder | Science Foundation Ireland | en_IE |
dc.contributor.funder | European Regional Development Fund | en_IE |
dc.contributor.funder | Horizon 2020 | en_IE |
dc.contributor.funder | Seventh Framework Programme | en_IE |
dc.internal.rssid | 20952281 | |
dc.local.contact | Matthew Dallas Griffin, Remedi, Biomedical Sciences Buil, Corrib Village, Dangan, Nui Galway. 5436 Email: matthew.griffin@nuigalway.ie | |
dc.local.copyrightchecked | Yes | |
dc.local.version | ACCEPTED | |
dcterms.project | info:eu-repo/grantAgreement/SFI/SFI Research Centres/13/RC/2073/IE/C�RAM - Centre for Research in Medical Devices/ | en_IE |
dcterms.project | info:eu-repo/grantAgreement/EC/H2020::MSCA-COFUND-FP/713690/EU/Career Development and Mobility Fellowships in Medical Device Research and Development: A CÚRAM Industry-Academia Training Initiative./MedTrain | en_IE |
dcterms.project | info:eu-repo/grantAgreement/EC/H2020::RIA/634086/EU/Novel Stromal Cell Therapy for Diabetic Kidney Disease/NEPHSTROM | en_IE |
dcterms.project | info:eu-repo/grantAgreement/EC/FP7::SP1::HEALTH/602470/EU/Adverse Immune Signatures and their Prevention in Corneal Transplantation/VISICORT | en_IE |
dcterms.project | info:eu-repo/grantAgreement/SFI/SFI Strategic Research Cluster/09/SRC/B1794/IE/SRC REMEDI: REMEDI-2: From Research to Human Therapy/ | en_IE |
nui.item.downloads | 52 | |